BioAge Labs (BIOA) reported late Tuesday that it plans to launch a public offering of up to $75 million of common shares.
Underwriters will be given a 30-day option to buy an additional $11.3 million of shares of its common stock, the company said.
The biopharma company said it plans to use the proceeds from offering, along with its existing cash, to finance the advancement of its product candidates, including lead candidate BGE-102, for debt reduction and general corporate purposes, among others.
Shares of the company fell more than 5% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments